Resverlogix Receives Approval From the FDA Cardiovascular and Renal Division to Proceed With a Requested Apabetalone Clinical Trial
– Apabetalone expands to a second major clinical indication in kidney dialysis patients Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) is pleased to announce the…